albireo
odevixibat
pfic
phase
results
accepted
aasld
final
pedfic
interim
pedfic
results
accepted
aasld
liver
meeting
pedfic
pedfic
largest
global
phase
children
pfic
types
two
abstracts
presented
new
pipeline
compound
boston
globe
newswire
albireo
pharma
nasdaq
albo
rare
liver
disease
company
developing
novel
bile
acid
modulators
today
announced
acceptances
american
association
study
liver
diseases
aasld
phase
pedfic
trial
pedfic
extension
trial
oral
presentation
results
pedfic
global
phase
clinical
trial
evaluating
efficacy
safety
odevixibat
children
progressive
familial
intrahepatic
cholestasis
pfic
session
pedfic
phase
extension
study
efficacy
safety
odevixibat
children
pfic
interim
results
presented
poster
addition
data
novel
bile
acid
modulator
approaches
new
product
candidate
also
accepted
poster
presentations
aasld
liver
meeting
digital
tlmdx
held
november
pedfic
achieved
high
statistical
significance
eu
primary
endpoints
eager
share
full
results
pedfic
program
date
odevixibat
sustained
reductions
bile
acids
pruritus
improved
growth
parameters
well
tolerated
low
incidence
diarrhea
across
wide
range
pfic
patients
said
ron
cooper
president
chief
executive
officer
albireo
scientific
leadership
pipeline
execution
also
shine
exciting
data
introducing
multiple
new
bile
acid
modulator
approaches
focusing
novel
compound
adult
liver
abstracts
available
aasld
website
details
abstracts
presented
november
published
december
issue
hepatology
presentation
efficacy
safety
odevixibat
ileal
bile
acid
transporter
inhibitor
children
progressive
familial
intrahepatic
cholestasis
types
results
pedfic
randomized
phase
trial
session
oral
abstract
session
presentation
lead
author
richard
thompson
professor
molecular
hepatology
king
college
london
principal
investigator
study
date
time
sunday
est
poster
efficacy
safety
odevixibat
ileal
bile
acid
transporter
inhibitor
children
progressive
familial
intrahepatic
cholestasis
interim
results
pedfic
phase
trial
session
abstract
posters
abstracts
accepted
earlier
month
published
october
issue
hepatology
included
one
abstract
selected
tlmdx
poster
distinction
top
percent
scored
poster
abstracts
poster
discovery
characterization
novel
bile
acid
transporter
inhibitors
potential
treatment
liver
diseases
session
biliary
transport
metabolism
poster
distinction
novel
inhibitor
bile
acid
transport
intestine
kidney
improves
markers
metabolic
hepatic
pathology
reduces
nonalcoholic
fatty
liver
disease
activity
score
fibrosis
stage
mouse
model
nonalcoholic
steatohepatitis
session
experimental
nafld
nash
odevixibat
odevixibat
investigational
product
candidate
developed
treat
rare
pediatric
cholestatic
liver
diseases
including
progressive
familial
intrahepatic
cholestasis
pfic
biliary
atresia
alagille
syndrome
highly
potent
ileal
bile
acid
transport
inhibitor
ibati
odevixibat
acts
locally
small
intestine
odevixibat
require
refrigeration
taken
capsule
older
children
opened
sprinkled
onto
food
factors
key
importance
adherence
pediatric
patient
population
albireo
conducted
largest
ever
global
phase
trial
pedfic
trial
evaluated
odevixibat
µg
kg
day
µg
kg
day
placebo
patients
ages
months
years
positive
results
trial
announced
september
news
release
albireo
phase
trial
meets
primary
endpoints
odevixibat
pfic
odevixibat
currently
evaluated
ongoing
pedfic
trial
bold
phase
trial
patients
biliary
atresia
initiation
pivotal
phase
trial
odevixibat
alagille
syndrome
also
anticipated
end
odevixibat
received
fast
track
rare
pediatric
disease
orphan
drug
designations
united
states
addition
fda
granted
orphan
drug
designation
odevixibat
treatment
alagille
syndrome
biliary
atresia
primary
biliary
cholangitis
ema
granted
odevixibat
orphan
designation
well
access
priority
medicines
prime
scheme
treatment
pfic
pediatric
committee
agreed
albireo
odevixibat
pediatric
investigation
plan
pfic
biliary
atresia
ema
also
granted
orphan
designation
odevixibat
treatment
alagille
syndrome
biliary
atresia
primary
biliary
cholangitis
odevixibat
potential
become
first
approved
drug
treatment
patients
pfic
company
intends
complete
regulatory
filings
eu
odevixibat
pfic
later
early
anticipation
potential
regulatory
approval
issuance
rare
pediatric
disease
priority
review
voucher
launch
second
half
albireo
albireo
pharma
biopharmaceutical
company
focused
development
novel
bile
acid
modulators
treat
rare
pediatric
adult
liver
diseases
adult
liver
diseases
disorders
albireo
lead
product
candidate
odevixibat
developed
treat
rare
pediatric
cholestatic
liver
diseases
phase
development
progressive
familial
intrahepatic
cholestasis
pfic
biliary
atresia
third
phase
trial
planned
alagille
syndrome
company
expects
complete
studies
new
preclinical
candidate
year
albireo
spun
astrazeneca
headquartered
boston
massachusetts
key
operating
subsidiary
gothenburg
sweden
boston
business
journal
named
albireo
one
best
places
work
massachusetts
second
consecutive
year
information
albireo
please
visit
statements
press
release
includes
statements
within
meaning
private
securities
litigation
reform
act
statements
include
statements
statements
historical
fact
regarding
among
things
plans
progress
scope
cost
initiation
duration
enrollment
results
timing
availability
results
development
odevixibat
albireo
product
candidate
program
including
regarding
expectations
regarding
impact
business
ability
adapt
approach
appropriate
phase
clinical
program
odevixibat
patients
pfic
pivotal
trial
odevixibat
biliary
atresia
bold
planned
pivotal
trial
odevixibat
alagille
syndrome
target
indication
development
approval
size
design
population
location
conduct
cost
objective
enrollment
duration
endpoints
clinical
trial
timing
initiation
completion
availability
reporting
results
clinical
trial
including
extension
study
odevixibat
pfic
pivotal
trial
odevixibat
biliary
atresia
planned
pivotal
trial
odevixibat
alagille
syndrome
potential
approval
commercialization
odevixibat
discussions
fda
ema
regarding
programs
potential
benefits
competitive
position
odevixibat
elobixibat
albireo
product
candidate
program
commercial
opportunity
target
indication
potential
effects
odevixibat
treatment
pfic
patients
potential
improve
current
standard
care
potential
benefits
orphan
drug
designation
potential
issuance
rare
pediatric
disease
priority
review
voucher
albireo
plans
expectations
future
operations
financial
position
revenues
costs
expenses
albireo
often
uses
words
anticipates
believes
plans
expects
projects
future
intends
may
could
estimates
predicts
potential
planned
continue
guidance
similar
expressions
identify
statements
actual
results
performance
experience
may
differ
materially
expressed
implied
statement
result
various
risks
uncertainties
factors
including
limited
negative
impacts
pandemic
including
manufacturing
supply
conduct
initiation
clinical
trials
aspects
business
whether
favorable
findings
clinical
trials
odevixibat
date
including
findings
indications
pfic
predictive
results
clinical
trials
odevixibat
whether
either
fda
ema
determine
primary
endpoint
respective
evaluations
treatment
duration
phase
trial
patients
pfic
sufficient
support
approval
odevixibat
united
states
european
union
treat
pfic
symptom
pfic
specific
pfic
subtype
otherwise
outcome
interpretation
regulatory
authorities
ongoing
study
pooling
analyzing
pfic
patient
data
timing
initiation
completion
availability
data
clinical
trials
odevixibat
including
pivotal
program
biliary
atresia
planned
pivotal
program
alagille
syndrome
outcomes
trials
albireo
ability
obtain
coverage
pricing
reimbursement
approved
products
united
states
european
union
delays
challenges
recruitment
patients
conduct
company
clinical
trials
albireo
critical
accounting
policies
risks
uncertainties
albireo
faces
described
greater
detail
heading
risk
factors
albireo
recent
annual
report
form
subsequent
filings
makes
securities
exchange
commission
result
risks
uncertainties
albireo
faces
results
events
indicated
statement
may
occur
albireo
cautions
place
undue
reliance
statement
addition
statement
press
release
represents
albireo
views
date
press
release
relied
upon
representing
views
subsequent
date
albireo
disclaims
obligation
update
statement
except
required
applicable
law
media
contacts
colleen
alabiso
heather
anderson
degrees
handerson
investor
contact
hans
vitzthum
lifesci
advisors
